NurExone Biologic Inc.

NurExone is building a regenerative exosome therapy platform. Its lead program targets central nervous system injury, with preclinical studies of acute spinal cord and optic nerve injury showing functional recovery after a short minimally-invasive treatment cycle.

Country

Israel

Website

nurexone.com

Founded

2020

Socials

Source of information:

nurexone.com

Add to My List

Key Executives

Yoram Drucker

Co-Founder, VP Strategic Development & Chairman

Lior Shaltiel, PhD

Chief Executive Officer & Director

Industries

Biotech

Add Your Company

Disclaimer

The content of this website is not directed at or intended for persons in the United Kingdom or any other jurisdiction where the provision of the website or services would breach any applicable law or registration or would require any registration or license in any such jurisdiction. The content of this website should not be regarded as an invitation or inducement to engage in investment activity, to any person in the United Kingdom and investment opportunities described on this website are not intended to be acted upon by any persons in the United Kingdom.